Ifeanyichukwu Ifechidere: When Fibrinogen isn’t Really Fibrinogen
Ifeanyichukwu Ifechidere, Specialist Biomedical Scientist at Sheffield Teaching Hospitals NHS Foundation Trust, shared a post on LinkedIn:
“When fibrinogen isn’t really fibrinogen…
A ‘normal’ or even elevated fibrinogen result can be reassuring.
But what if that number isn’t telling the full story?
Welcome to one of the most overlooked pitfalls in coagulation testing
The Clauss fibrinogen assay – trusted, but not foolproof
The Clauss method measures functional fibrinogen by assessing clot formation after high thrombin concentration.
But here’s the catch:
It assumes fibrinogen is functionally normal
When it’s not… results can mislead.
Dysfibrinogenemia: the great imitator
In dysfibrinogenemia, fibrinogen antigen levels may be normal… but function is impaired.
What you might see:
Discrepancy between Clauss fibrinogen (low) and antigen (normal)
Unexplained bleeding… or paradoxically, thrombosis
Prolonged clotting times (sometimes subtle, sometimes not)
In other words:
There is fibrinogen present — it just doesn’t work properly
But it’s not always dysfibrinogenemia…
The Clauss assay can be affected by multiple interferences:
- Direct thrombin inhibitors (e.g. dabigatran)
- Heparin (depending on reagent sensitivity)
- High FDPs / D-dimer
- Paraproteins
- Severe inflammation
All of these can – falsely low functional fibrinogen
So what should you do?
- Correlate with clinical context
- Compare functional vs antigen fibrinogen
- Review medications and interferences
- Consider reptilase time or genetic testing if needed
Take-home message
Not all fibrinogen results reflect true functional capacity.
Sometimes, what looks like ‘low fibrinogen’ is actually a measurement limitation – or a dysfunctional molecule hiding in plain sight.
Want more clear, practical insights into coagulation testing pitfalls?”

More posts featuring Ifeanyichukwu Ifechidere on Hemostasis Today.
-
Aug 26, 2026, 14:03Ahmad Masri: The Amyloid Depleter Revolution in ATTR-CM
-
Aug 26, 2026, 13:59David McIntosh: Immunoglobulin Stewardship in the Face of Rising Demand
-
Aug 26, 2026, 13:54Giuseppe Biondi Zoccai: Congratulations to the Next Editor-in-Chief of the EHJ
-
Aug 26, 2026, 13:25Omar Adwan: Abnormal Nuclear Morphology of Neutrophil
-
Aug 26, 2026, 13:05Preventing Thrombosis with WTDay26
-
Aug 26, 2026, 10:09Gemma Figtree: How Well Do We Predict Heart Attack Risk in Women?
-
Aug 26, 2026, 10:06Understanding and Managing Fatigue in ITP – ITP Support Association
-
Aug 26, 2026, 10:04Abdul Muqtadir Abbasi: When a High INR Hides a Thrombotic Cancer
-
Aug 26, 2026, 09:42Mohammed Alo: What’s Wrong With the New Blood Pressure Guidelines?